The CHIKVAX project — Development of a new generation of vaccines: prototype vaccine against the Chikungunya virus — is an industrial R§D project that aims to develop a vaccine against an existing viral threat to millions of individuals and a probable threat to the population of southern France, southern Europe and the south of the USA + the possibility of developing in real time vaccines against future increasingly probable viral pandemics. The objective of the project is the development of a fully innovative technology enabling the rapid development of vaccine candidates preventive against viral threats, which can be rapidly deployable in the event of pandemics and require little or no adjuvants. The validation of this technology is done on the Chikungunya virus. This project is a collaborative RDI project conducted over 36 months, It has been validated by the State under FUI 21 and brings together the following 4 industrial and academic partners: companies CILOA — Lead (SME Montpellier — Dpt 34), Calixar (PME Lyon — Dpt 69) — Institut National de la Santé et de la Recherche Médicale — INSERM — (Créteil Dpt 94) — Institut PASTEUR (Paris Dpt 75). It has been labeled by the competitiveness cluster EUROBIOMED — drug business axis — thematic of immunology excellence. For CILOA, the only regional partner, the choice of funding was made by the European ERDF funds.